Why the study?
Does pimozide improve clinical symptoms compared to chlorpromazine in patients with mania?
Does pimozide improve clinical symptoms compared to chlorpromazine in patients with mania?
Pimozide is as effective as chlorpromazine in the treatment of mania, supporting the hypothesis that hyperactivity of central dopamine pathways is involved in its pathogenesis.
Answers are grounded in this paper and cite their sources.
Pimozide matches chlorpromazine for acute mania; confirms central dopamine hyperactivity in pathogenesis.
Pimozide (PMZ), a relatively specific dopamine (DA) receptor blocking drug, was compared to chlorpromazine (CPZ) in a double-blind, between-patient clinical trial in mania. The trial lasted 14 days. Twenty-three patients who fulfilled Feighner's criteria for mania entered the trial (one patient entering on two separate occasions). Both drugs led to clinical improvement, with a significant effect being noted within 24 hours. According to one of the two rating scales used, initial improvement was greater with chlorpromazine, probably due to its greater sedative effect. By 7 days both drugs were equally effective. Sedative side effects were more frequent in patients on CPZ; extrapyramidal side effects were more frequent with PMZ. The finding that the relatively specific DA receptor blocking drug PMZ was as effective as CPZ in the treatment of mania is consistent with the view that hyperactivity of central DA pathways is involved in the pathogenesis of this condition.
No takes yet. Share an insight, caveat, or question.
Cookson et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: